Personalized mRNA melanoma vaccine just cut recurrence/death risk by 42% in Phase 3. After decades of cancer vaccine failures, this tech is finally delivering. Absolute game-changer for patients. We are living in an age of miracles. @NYTimes
nytimes.com/2026/10/23/wel…
nytimes.com/2026/10/23/wel…